A promising solution to a cancer drug resistance problem

A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of BTK inhibitor treatment resistance.BTK inhibitors reduce the activity of the enzyme BTK (Bruton’s Tyrosine Kinase), which has a central role in immune cells called B cells.